Trial Profile
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Cetuximab sarotalocan (Primary) ; Cetuximab; Docetaxel; Methotrexate; Paclitaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUZERA-301
- Sponsors Aspyrian Therapeutics; Rakuten Medical
- 06 Mar 2024 According to a Rakuten Medical media release, company announced the completion of a $119 million Series E preferred stock financing, including $45 million in new capital and the conversion of $74 million of convertible promissory notes with accrued interest to accelerate its global Phase 3 study with the goal of achieving approval of ASP-1929 in US as soon as possible.
- 22 Jan 2024 According to a Rakuten Medical media release, company announced that the first patient in India received study treatment in August 2023. In India, 6 leading medical institutions are currently participating in this trial. Dr. Subramania Iyer K., is an investigator for the this study at the Amrita Institute of Medical Sciences and Research Centre (Kochi).
- 18 Jul 2023 According to a Rakuten Medical media release, the company will host a virtual R&D Day to provide update from this trial; The webinar will take place on Thursday, August 10, 2023 at 8:30 AM PT / 11:30 AM ET; A live question and answer session will follow the formal presentation. Parties interested in participating in this event should click here to register and access the live webcast